Molecular profile of liquid biopsies: Next generation biomarkers to improve lung cancer treatment

Research output: Contribution to journalArticle

Abstract

Molecular profiling of liquid biopsies is now emerging as pivotal for cancer biomarker discovery. The low-invasive nature of the approach used for collecting biospecimens (i.e. blood, urine, saliva, etc.) may allow a widespread application of novel molecular diagnostics based on liquid biopsies. This is relevant, for example, in cancer screening programmes where it is essential to reduce costs and the complexity of screening tests in order to increase study compliance and effectiveness. Here, I discuss recent advances in biomarkers for the early cancer detection and prediction of chemotherapy response based on the molecular profiling of liquid biopsies.

Original languageEnglish
Article number598
Journalecancermedicalscience
Volume9
DOIs
Publication statusPublished - Nov 24 2015

Fingerprint

Lung Neoplasms
Biomarkers
Biopsy
Early Detection of Cancer
Molecular Pathology
Tumor Biomarkers
Saliva
Compliance
Therapeutics
Urine
Costs and Cost Analysis
Drug Therapy

Keywords

  • Biomarkers
  • Circulating biomarkers
  • Circulating tumour DNA
  • Lung cancer
  • MicroRNA

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{dcbef58ad7ef41e6a58bc4bb19fafd6d,
title = "Molecular profile of liquid biopsies: Next generation biomarkers to improve lung cancer treatment",
abstract = "Molecular profiling of liquid biopsies is now emerging as pivotal for cancer biomarker discovery. The low-invasive nature of the approach used for collecting biospecimens (i.e. blood, urine, saliva, etc.) may allow a widespread application of novel molecular diagnostics based on liquid biopsies. This is relevant, for example, in cancer screening programmes where it is essential to reduce costs and the complexity of screening tests in order to increase study compliance and effectiveness. Here, I discuss recent advances in biomarkers for the early cancer detection and prediction of chemotherapy response based on the molecular profiling of liquid biopsies.",
keywords = "Biomarkers, Circulating biomarkers, Circulating tumour DNA, Lung cancer, MicroRNA",
author = "Fabrizio Bianchi",
year = "2015",
month = "11",
day = "24",
doi = "10.3332/ecancer.2015.598",
language = "English",
volume = "9",
journal = "ecancermedicalscience",
issn = "1754-6605",
publisher = "Cancer Intellilgence",

}

TY - JOUR

T1 - Molecular profile of liquid biopsies

T2 - Next generation biomarkers to improve lung cancer treatment

AU - Bianchi, Fabrizio

PY - 2015/11/24

Y1 - 2015/11/24

N2 - Molecular profiling of liquid biopsies is now emerging as pivotal for cancer biomarker discovery. The low-invasive nature of the approach used for collecting biospecimens (i.e. blood, urine, saliva, etc.) may allow a widespread application of novel molecular diagnostics based on liquid biopsies. This is relevant, for example, in cancer screening programmes where it is essential to reduce costs and the complexity of screening tests in order to increase study compliance and effectiveness. Here, I discuss recent advances in biomarkers for the early cancer detection and prediction of chemotherapy response based on the molecular profiling of liquid biopsies.

AB - Molecular profiling of liquid biopsies is now emerging as pivotal for cancer biomarker discovery. The low-invasive nature of the approach used for collecting biospecimens (i.e. blood, urine, saliva, etc.) may allow a widespread application of novel molecular diagnostics based on liquid biopsies. This is relevant, for example, in cancer screening programmes where it is essential to reduce costs and the complexity of screening tests in order to increase study compliance and effectiveness. Here, I discuss recent advances in biomarkers for the early cancer detection and prediction of chemotherapy response based on the molecular profiling of liquid biopsies.

KW - Biomarkers

KW - Circulating biomarkers

KW - Circulating tumour DNA

KW - Lung cancer

KW - MicroRNA

UR - http://www.scopus.com/inward/record.url?scp=84960399035&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960399035&partnerID=8YFLogxK

U2 - 10.3332/ecancer.2015.598

DO - 10.3332/ecancer.2015.598

M3 - Article

AN - SCOPUS:84960399035

VL - 9

JO - ecancermedicalscience

JF - ecancermedicalscience

SN - 1754-6605

M1 - 598

ER -